MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

MDT

87.56

+0.44%↑

A

114.42

-2.15%↓

VEEV

160

-7.43%↓

HQY

83.34

+1.87%↑

TLRY

6.65

-1.92%↓

Search

Cytek Biosciences Inc

Открыт

СекторЗдравоохранение

4.6 -2.75

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

4.45

Макс.

4.6899999999999995

Ключевые показатели

By Trading Economics

Доход

-39M

-44M

Продажи

9.8M

62M

Рентабельность продаж

-70.929

Сотрудники

702

EBITDA

4M

-263K

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+35.87% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

7 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

20M

581M

Предыдущая цена открытия

7.35

Предыдущая цена закрытия

4.6

Новостные настроения

By Acuity

50%

50%

168 / 349 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

Cytek Biosciences Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

8 апр. 2026 г., 20:44 UTC

Отчет

Costco Reports 11% Growth in March Sales

8 апр. 2026 г., 23:51 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

8 апр. 2026 г., 23:51 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8 апр. 2026 г., 23:36 UTC

Обсуждения рынка
Главные новостные события

Gold Edges Lower on Likely Technical Correction -- Market Talk

8 апр. 2026 г., 22:56 UTC

Обсуждения рынка

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8 апр. 2026 г., 22:45 UTC

Обсуждения рынка

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8 апр. 2026 г., 22:17 UTC

Обсуждения рынка

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8 апр. 2026 г., 21:52 UTC

Главные новостные события

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8 апр. 2026 г., 21:24 UTC

Отчет

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8 апр. 2026 г., 21:01 UTC

Главные новостные события

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8 апр. 2026 г., 20:50 UTC

Обсуждения рынка

Energy & Utilities Roundup: Market Talk

8 апр. 2026 г., 20:43 UTC

Приобретения, слияния, поглощения

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8 апр. 2026 г., 20:43 UTC

Приобретения, слияния, поглощения

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8 апр. 2026 г., 20:43 UTC

Приобретения, слияния, поглощения

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8 апр. 2026 г., 20:42 UTC

Приобретения, слияния, поглощения

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8 апр. 2026 г., 20:42 UTC

Приобретения, слияния, поглощения

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8 апр. 2026 г., 20:42 UTC

Приобретения, слияния, поглощения

Oracle Responds to TRC Cap Mini-Tender Offer

8 апр. 2026 г., 20:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

8 апр. 2026 г., 20:11 UTC

Приобретения, слияния, поглощения

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8 апр. 2026 г., 20:11 UTC

Приобретения, слияния, поглощения

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8 апр. 2026 г., 20:11 UTC

Приобретения, слияния, поглощения

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8 апр. 2026 г., 19:44 UTC

Отчет

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8 апр. 2026 г., 19:16 UTC

Обсуждения рынка

Hogs Follow Cutout Prices Lower -- Market Talk

8 апр. 2026 г., 19:02 UTC

Обсуждения рынка

Global Energy Roundup: Market Talk

8 апр. 2026 г., 19:02 UTC

Обсуждения рынка

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8 апр. 2026 г., 18:58 UTC

Обсуждения рынка

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8 апр. 2026 г., 18:51 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

8 апр. 2026 г., 18:51 UTC

Обсуждения рынка

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8 апр. 2026 г., 18:14 UTC

Главные новостные события

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8 апр. 2026 г., 18:05 UTC

Главные новостные события

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Сравнение c конкурентами

Изменение цены

Cytek Biosciences Inc Прогноз

Целевая цена

By TipRanks

35.87% рост

Прогноз на 12 месяцев

Средняя 6.25 USD  35.87%

Максимум 7.5 USD

Минимум 5 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Cytek Biosciences Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

1

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

3.7 / 3.8Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

168 / 349Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat